Want to see DVA full AI Analyst Report?
DVA Stock Chart & Stats
$235.44
$1.05(0.45%)
At close: 4:00 PM EDT
$235.44
$1.05(0.45%)
Day’s Range― - ―
52-Week Range$101.00 - $239.64
Previous CloseN/A
Volume215.97K
Average Volume (3M)761.53K
Market Cap
$15.12B
Enterprise Value$24.86K
Total Cash (Recent Filing)$748.71M
Total Debt (Recent Filing)$13.22B
Price to Earnings (P/E)23.2
Beta0.50
Next Earnings
Aug 04, 2026EPS Estimate
3.88Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)10.15
Shares Outstanding64,200,000
10 Day Avg. Volume607,188
30 Day Avg. Volume761,531
Financial Highlights & Ratios
PEG Ratio-0.99
Price to Book (P/B)-15.02
Price to Sales (P/S)0.72
P/FCF Ratio7.46
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$231.80Price Target Upside-1.55% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)14.88
Revenue Forecast (FY)$14.09B
Bulls Say, Bears Say
Bulls Say
Robust Cash GenerationSustained operating cash flow and near-$1.5B free cash flow provide durable internal funding for capex, clinical investments, and debt reduction. Strong cash generation improves resilience to reimbursement variability and supports strategic initiatives without relying solely on external financing.
Healthy Operating Margins And Steady Revenue GrowthConsistently above-average operating and EBITDA margins and multi-year revenue growth indicate durable efficiency in dialysis operations and pricing power versus peers. Margin strength supports reinvestment and cushions against cyclical reimbursement or volume pressure over the medium term.
Strategic Tech And AI Investments To Boost ProductivityCompany-wide data and AI initiatives target scheduling, EMR efficiency and caregiver productivity, offering structural cost and quality advantages as scale grows. These platform investments can lower unit labor costs and improve capacity utilization over time, strengthening long-term operating leverage.
Bears Say
Very High Leverage And Negative EquityElevated leverage with negative shareholders' equity materially limits financial flexibility and raises refinancing and covenant risk. This structural balance-sheet imbalance makes the company more vulnerable to reimbursement shocks or prolonged margin pressure and constrains strategic optionality.
Material Interest Expense BurdenSustained high interest expense is a recurring cash drain that reduces free cash flow available for deleveraging or reinvestment. Persistent debt servicing needs increase sensitivity to interest rates and limit the pace at which leverage can be meaningfully reduced without curbing other strategic investments.
Payer-mix And ACA Enrollment UncertaintyShifts in payer mix and ACA enrollment can structurally lower revenue per treatment and raise patient out-of-pocket costs. Because a large share of revenue derives from government and insurance reimbursements, adverse mix shifts can persistently pressure top-line growth and margins over the medium term.
DaVita News
DVA FAQ
What was DaVita’s price range in the past 12 months?
DaVita lowest stock price was $101.00 and its highest was $239.64 in the past 12 months.
What is DaVita’s market cap?
DaVita’s market cap is $15.12B.
When is DaVita’s upcoming earnings report date?
DaVita’s upcoming earnings report date is Aug 04, 2026 which is in 7 days.
How were DaVita’s earnings last quarter?
DaVita released its earnings results on May 05, 2026. The company reported $2.87 earnings per share for the quarter, beating the consensus estimate of $2.33 by $0.54.
Is DaVita overvalued?
According to Wall Street analysts DaVita’s price is currently Overvalued.
Does DaVita pay dividends?
DaVita does not currently pay dividends.
What is DaVita’s EPS estimate?
DaVita’s EPS estimate is 3.88.
How many shares outstanding does DaVita have?
DaVita has 64,200,000 shares outstanding.
What happened to DaVita’s price movement after its last earnings report?
DaVita reported an EPS of $2.87 in its last earnings report, beating expectations of $2.33. Following the earnings report the stock price went up 23.459%.
Which hedge fund is a major shareholder of DaVita?
Currently, no hedge funds are holding shares in DVA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
DaVita Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$231.80 (-1.55% Downside)
$231.80 (-1.55% Downside)
Blogger Sentiment
Neutral
DVA Sentiment 57%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.7M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $33.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.0%
Last 30 Days ▲ 10.4%
Last 30 Days ▲ 10.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
62.63%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
2.22%
Trailing 12-Months
Company Description
DaVita
DaVita Inc. specializes in delivering essential kidney dialysis treatments and comprehensive renal care to individuals grappling with chronic kidney failure. The company primarily operates an extensive network of outpatient dialysis centers, supplementing this with services provided in hospital inpatient settings and within patients' homes. Beyond direct patient treatment, DaVita manages its own diagnostic laboratories, performing routine tests vital for dialysis patients, alongside other physician-ordered laboratory analyses specifically for those with end-stage renal disease (ESRD). The firm also offers administrative and management support to various other outpatient dialysis facilities. Its broad spectrum of offerings extends to chronic disease management programs, supporting a substantial patient cohort; by year-end 2021, this included 16,000 patients enrolled in risk-based integrated care models and an additional 7,000 in other integrated care arrangements. Further specialized services encompass vascular access interventions, clinical research initiatives, direct physician support, and a complete suite of holistic kidney care solutions. As of December 31, 2021, DaVita's footprint across the United States comprised 2,815 outpatient dialysis centers, collectively serving approximately 203,100 patients. Globally, the company operated 339 outpatient dialysis centers spread across ten countries outside the U.S., attending to roughly 39,900 patients. Moreover, it furnished acute inpatient dialysis services and related laboratory work in around 850 U.S. hospitals. Founded in 1994, DaVita Inc. maintains its headquarters in Denver, Colorado. The company rebranded to its current name in September 2016, having previously been known as DaVita HealthCare Partners Inc.
DVA Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call reflected a generally positive tone: the company beat Q1 expectations, raised and narrowed full-year adjusted operating income and EPS guidance, demonstrated productivity-led cost improvements, and highlighted strong IKC clinical and savings performance. Material investments in technology and AI were emphasized as strategic drivers of future clinical and operational outperformance. Offsetting items included near-term pressure from higher G&A (driven by technology spend), an IKC operating loss, modest treatment declines versus prior year, ACA enrollment/mix uncertainty that could pressure revenue per treatment later in the year, and unchanged free cash flow guidance. On balance, the positive beats, guidance raise, and structural investments outweighed the near-term headwinds.View all DVA earnings summariesDVA Revenue Breakdown
85.99% U.S. dialysis
14.01% Ancillary services
DVA Stock 12 Month Forecast
Average Price Target
$231.80
▼(-1.55% Downside)
Technical Analysis
Fresenius Medical Care
―
HCA Healthcare
―
Encompass Health
―
Tenet Healthcare
―
The Ensign Group
―
Ownership Overview
47.00% Insiders
10.82% Mutual Funds
0.71% Other Institutional Investors
25.78% Public Companies and
Individual Investors